<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>pharmaceuticals on FinanClub</title>
    <link>https://finan.club/tags/pharmaceuticals/</link>
    <description>Recent content in pharmaceuticals on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 26 Jan 2024 09:05:43 +0000</lastBuildDate><atom:link href="https://finan.club/tags/pharmaceuticals/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Fri, 26 Jan 2024 09:05:43 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:174
Chances: Merck &amp;amp; Co., Inc. is engaged in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care productsThe company operates in Pharmaceutical, Animal Health, and Other segmentsIt has entered into a clinical trial collaboration agreement with LAVA Therapeutics NV for evaluation of its anti-PD-1 therapy Keytruda Risks: The company&amp;rsquo;s stock price might be vulnerable to the large stake held by institutionsUncertainty around the future of stock markets remains highThe Senate HELP committee is seeking testimony from the company Score:174 chances characters count - risks characters count = 174</description>
    </item>
    
    <item>
      <title>OGN</title>
      <link>https://finan.club/us/ogn/</link>
      <pubDate>Wed, 20 Dec 2023 09:03:44 +0000</pubDate>
      
      <guid>https://finan.club/us/ogn/</guid>
      <description>score:21
Chances: Organon&amp;rsquo;s partnership with Sempre Health to improve medication adherence shows a proactive approach to patient care and may lead to increased sales. The company&amp;rsquo;s exclusive distribution of Emgality and RAYVOW in Europe presents a significant opportunity for revenue growth in the region.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
